
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4066711</article-id><article-id pub-id-type="doi">10.1155/2014/364625</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Wen-Yuan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Kuan-Chung</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hsin-Yi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Calvin Yu-Chian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan</aff><aff id="I2"><sup>2</sup>School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan</aff><aff id="I3"><sup>3</sup>Department of Neurosurgery, China Medical University Hospital, Taichung 40447, Taiwan</aff><aff id="I4"><sup>4</sup>School of Pharmacy, China Medical University, Taichung 40402, Taiwan</aff><aff id="I5"><sup>5</sup>Research Center for Chinese Medicine &amp; Acupuncture, China Medical University, Taichung 40402, Taiwan</aff><author-notes><corresp id="cor1">*Calvin Yu-Chian Chen: <email>ycc929@MIT.edu</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Chung Y. </plain></SENT>
<SENT sid="2" pm="."><plain>Hsu </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>6</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>364625</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>4</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>4</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Wen-Yuan Lee et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>A recent research of cancer has indicated that the mutant of isocitrate dehydrogenase 1 and 2 (IDH1 and 2) genes will induce various cancers, including chondrosarcoma, cholangiocarcinomas, and acute myelogenous leukemia due to the effect of point mutations in the active-site arginine residues of isocitrate dehydrogenase (IDH), such as IDH1/R132, IDH2/R140, and IDH2/R172. </plain></SENT>
<SENT sid="4" pm="."><plain>As the inhibition for those tumor-associated mutant IDH proteins may induce differentiation of those cancer cells, these tumor-associated mutant IDH proteins can be treated as a drug target proteins for a differentiation therapy against cancers. </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we aim to identify the potent TCM compounds from the TCM Database@Taiwan as lead compounds of IDH2 R140Q mutant inhibitor. </plain></SENT>
<SENT sid="6" pm="."><plain>Comparing to the IDH2 R140Q mutant protein inhibitor, AGI-6780, the top two TCM compounds, precatorine and abrine, have higher binding affinities with target protein in docking simulation. </plain></SENT>
<SENT sid="7" pm="."><plain>After MD simulation, the top two TCM compounds remain as the same docking poses under dynamic conditions. </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, precatorine is extracted from Abrus precatorius L., which represents the cytotoxic and proapoptotic effects for breast cancer and several tumor lines. </plain></SENT>
<SENT sid="9" pm="."><plain>Hence, we propose the TCM compounds, precatorine and abrine, as potential candidates as lead compounds for further study in drug development process with the IDH2 R140Q mutant protein against cancer. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="10" pm="."><plain>1. </plain></SENT>
<SENT sid="11" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Nowadays, in accordance with more and more mechanisms of diseases being identified [1–6], there are increasing numbers of potential target proteins against each disease, which are useful for drug design [7–11]. </plain></SENT>
<SENT sid="13" pm="."><plain>The recent research of cancer has indicated that the mutant of isocitrate dehydrogenase 1 and 2 (IDH1 and 2) genes will induce various cancers [12, 13]. </plain></SENT>
<SENT sid="14" pm="."><plain>Somatic mutations in the isocitrate dehydrogenase 1 and 2 genes affecting point mutations in the active-site arginine residues of isocitrate dehydrogenase (IDH), such as IDH1/R132, IDH2/R140, and IDH2/R172, occur frequently in many cancers, including chondrosarcoma, cholangiocarcinomas, and acute myelogenous leukemia [14–22]. </plain></SENT>
<SENT sid="15" pm="."><plain>The inhibition for those tumor-associated mutant IDH proteins may induce differentiation of those cancer cells. </plain></SENT>
<SENT sid="16" pm="."><plain>The tumor-associated mutant IDH proteins can be treated as a drug target proteins for a differentiation therapy against cancers [23]. </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>Nowadays, the computer-aided drug design has been widely used in drug designing [24, 25]. </plain></SENT>
<SENT sid="18" pm="."><plain>Increasing numbers of compounds extracted from traditional Chinese medicine (TCM) have been indicated as potential lead compounds against cancers [26–28], inflammation [29], influenza [30], viral infection [31], metabolic syndrome [32], diabetes [33], stroke [34–36], and many other diseases [37–41]. </plain></SENT>
<SENT sid="19" pm="."><plain>A recent research of mutant IDH2 protein shows a compound, AGI-6780, which can inhibit the tumor-associated mutant IDH2/R140Q [42]. </plain></SENT>
<SENT sid="20" pm="."><plain>For drug development of TCM compounds, we aim to identify the potent TCM compounds from the TCM Database@Taiwan [43] as lead compounds of IDH2 R140Q mutant inhibitor. </plain></SENT>
<SENT sid="21" pm="."><plain>As structural disordered disposition in the protein may induce the side effect and reduce the occupancy for ligand to bind with target protein [44, 45], PONDR-Fit protocol was performed to predict the disordered disposition in IDH2 protein before virtual screening. </plain></SENT>
<SENT sid="22" pm="."><plain>After virtual screening, the MD simulation was performed to validate the stability of interactions between IDH2 R140Q mutant proteins and each ligand. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="sec2"><title><text><SENT sid="23" pm="."><plain>2. </plain></SENT>
<SENT sid="24" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec2.1"><title><text><SENT sid="25" pm="."><plain>2.1. </plain></SENT>
<SENT sid="26" pm="."><plain>Data Collection </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>The X-ray crystallography structure of the human mitochondrial isocitrate dehydrogenase (IDH2) R140Q mutant was downloaded from RCSB Protein Data Bank with PDB ID: 4JA8 [42]. </plain></SENT>
<SENT sid="28" pm="."><plain>To predict the disordered amino acids, PONDR-Fit [46] protocol was employed with the sequence of IDH2 protein from Swiss-Prot (UniProtKB: P48735). </plain></SENT>
<SENT sid="29" pm="."><plain>In preparation section, X-ray crystallography structure of IDH2 R140Q mutant protein was protonated with Chemistry at HARvard Macromolecular Mechanics (CHARMM) force field [47] and removed crystal water by Prepare Protein module in Discovery Studio 2.5 (DS2.5). </plain></SENT>
<SENT sid="30" pm="."><plain>The final structure of TCM compounds from TCM Database@Taiwan [43] was protonated and filtered by Lipinski's Rule of Five [48] using Prepare Ligand module in DS2.5. </plain></SENT>
<SENT sid="31" pm="."><plain>The binding site for virtual screening was defined by the volume of the cocrystallized IDH2 R140Q mutant inhibitor, AGI-6780. </plain></SENT>
</text></p></sec><sec id="sec2.2"><title><text><SENT sid="32" pm="."><plain>2.2. </plain></SENT>
<SENT sid="33" pm="."><plain>Docking Simulation </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>The TCM compounds were docking into the binding site using a shape filter and Monte-Carlo ligand conformation generation by LigandFit protocol [49] in DS 2.5. </plain></SENT>
<SENT sid="35" pm="."><plain>The docking poses were optionally minimized with CHARMM force field [47] and filtered the similar poses by the clustering algorithm. </plain></SENT>
<SENT sid="36" pm="."><plain>Each docking pose was evaluated by the following Dock Score energy function: Dock Score = − (ligand/receptor interaction energy + ligand internal energy). </plain></SENT>
</text></p></sec><sec id="sec2.3"><title><text><SENT sid="37" pm="."><plain>2.3. </plain></SENT>
<SENT sid="38" pm="."><plain>Molecular Dynamics (MD) Simulation </plain></SENT>
</text></title><p><text><SENT sid="39" pm="."><plain>The molecular dynamics (MD) simulation utilizing Gromacs 4.5.5 [50] was employed using classical molecular dynamics theory to simulate each protein-ligand complex under dynamic conditions. </plain></SENT>
<SENT sid="40" pm="."><plain>In preparation section, the IDH2 R140Q mutant proteins were prepared by pdb2gmx protocol of Gromacs to provide topology and parameters with charmm27 force field, and each ligand was prepared by SwissParam program [51]. </plain></SENT>
<SENT sid="41" pm="."><plain>A cubic box solvated using TIP3P water model was defined based upon the edge approx. </plain></SENT>
<SENT sid="42" pm="."><plain>1.2 nm from the protein complexes periphery. </plain></SENT>
<SENT sid="43" pm="."><plain>In the minimization section, the steepest descent [52] minimization was employed with a maximum of 5,000 steps to remove bad van der Waals contacts. </plain></SENT>
<SENT sid="44" pm="."><plain>Gromacs program creates a neutral system using 0.145 M NaCl model, followed by another steepest descent minimization with a maximum of 5,000 steps to remove bad van der Waals contacts. </plain></SENT>
<SENT sid="45" pm="."><plain>In the equilibration section, Gromacs program performs a position-restrained molecular dynamics with the linear constraint algorithm for all bonds, NVT equilibration, Berendsen weak thermal coupling method, and particle mesh Ewald method. </plain></SENT>
<SENT sid="46" pm="."><plain>In the production section, Gromacs program performs a total of 5000 ps production simulation with time step in unit of 2 fs under NPT ensembles and particle mesh Ewald (PME) option. </plain></SENT>
<SENT sid="47" pm="."><plain>A series of protocols in Gromacs program was utilized to analyze the 5000 ps MD trajectories. </plain></SENT>
<SENT sid="48" pm="."><plain>The CAVER 3.0 [53] was employed to analyze the presumably pathways for small molecule under dynamics conditions. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec id="sec3"><title><text><SENT sid="49" pm="."><plain>3. </plain></SENT>
<SENT sid="50" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><sec id="sec3.1"><title><text><SENT sid="51" pm="."><plain>3.1. </plain></SENT>
<SENT sid="52" pm="."><plain>Disordered Protein Prediction </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>The sequence of IDH2 protein from Swiss-Prot (UniProtKB: P48735) was employed to predict the disordered disposition by PONDR-Fit protocol. </plain></SENT>
<SENT sid="54" pm="."><plain>As illustrated in Figure 1, the key residues in the binding domain have no disordered disposition, which express a stable binding domain in protein folding. </plain></SENT>
<SENT sid="55" pm="."><plain>It indicates that the binding domain in the crystallography structure of target protein will be suitable for docking simulation as the residues in the binding domain have no significant variation. </plain></SENT>
</text></p></sec><sec id="sec3.2"><title><text><SENT sid="56" pm="."><plain>3.2. </plain></SENT>
<SENT sid="57" pm="."><plain>Docking Simulation </plain></SENT>
</text></title><p><text><SENT sid="58" pm="."><plain>To validate the accuracy of LigandFit protocol, we redock the cocrystallized IDH2 R140Q mutant inhibitor, AGI-6780, into the binding site of IDH2 R140Q mutant proteins. </plain></SENT>
<SENT sid="59" pm="."><plain>Root-mean-square deviation (RMSD) value between crystallized structure and docking pose of AGI-6780 is 0.3683 Å (Figure 2), which indicates that the docking simulation by LigandFit protocol is suitable for virtual screening with IDH2 R140Q mutant proteins. </plain></SENT>
<SENT sid="60" pm="."><plain>After virtual screening, the chemical scaffolds of AGI-6780 and top two TCM compounds are displayed in Figure 3 with Dock Score and sources. </plain></SENT>
<SENT sid="61" pm="."><plain>Precatorine is extracted from Abrus precatorius L., and abrine is extracted from Abrus fruticuIosus Wall. ex Wight et Arn. The compounds extracted from Abrus precatorius L. had been indicated to have the antimicrobial activity [54], antibacterial activity [55], cytotoxic and proapoptotic effects for breast cancer [56], and several tumor lines [57].  Figure 4 illustrated the docking poses of IDH2 R140Q mutant protein complexes with AGI-6780 and top two TCM compounds, respectively. </plain></SENT>
<SENT sid="62" pm="."><plain>The IDH2 R140Q mutant protein inhibitor, AGI-6780, has hydrogen bonds (H-bonds) with residues Gln316 in both chains of IDH2 R140Q mutant protein and a π interaction with residue Ile319 in chain B of IDH2 R140Q mutant protein. </plain></SENT>
<SENT sid="63" pm="."><plain>For the top TCM candidates, they also have H-bonds with residues Gln316 in both chains of IDH2 R140Q mutant protein as AGI-6780. </plain></SENT>
<SENT sid="64" pm="."><plain>For abrine, it has a π interaction with residue Ile319 in chain A of IDH2 R140Q mutant protein. </plain></SENT>
</text></p></sec><sec id="sec3.3"><title><text><SENT sid="65" pm="."><plain>3.3. </plain></SENT>
<SENT sid="66" pm="."><plain>Molecular Dynamics Simulation </plain></SENT>
</text></title><p><text><SENT sid="67" pm="."><plain>For the docking simulation performed by LigandFit protocol, the receptor is a rigid body of IDH2 R140Q mutant proteins. </plain></SENT>
<SENT sid="68" pm="."><plain>The conformation of the IDH2 R140Q mutant protein may modify under dynamic conditions. </plain></SENT>
<SENT sid="69" pm="."><plain>We employed the MD simulation to validate the stability of interactions between IDH2 R140Q mutant proteins and each ligand. </plain></SENT>
<SENT sid="70" pm="."><plain>RMSDs illustrated the atomic fluctuations during MD simulation.  Figure 5 displays the atomic fluctuations of IDH2 R140Q mutant proteins in apo form and complexes with AGI-6780, precatorine, and abrine and the atomic fluctuations of each compound during 5000 ps MD simulation. </plain></SENT>
<SENT sid="71" pm="."><plain>It shows that IDH2 R140Q mutant proteins tend to be stable after first 100 ps MD simulation, but the ligands except precatorine are fluctuate during MD simulation. </plain></SENT>
<SENT sid="72" pm="."><plain>To consider the variation radii of gyration for protein and total energy over 5000 ps MD simulation in Figure 6, it indicates that the radii of gyration for IDH2 R140Q mutant proteins in apo form were decreased after 4500 ps MD simulation, but the radii of gyration for complexes of IDH2 R140Q mutant proteins with AGI-6780, precatorine, and abrine were more stabilized. </plain></SENT>
<SENT sid="73" pm="."><plain>In addition, there is no significant change for the total energies of each IDH2 R140Q mutant protein complex during MD simulation in Figure 7. </plain></SENT>
<SENT sid="74" pm="."><plain>The variation of solvent accessible surface area over 5000 ps MD simulation in Figure 8 indicates that docking the ligands, AGI-6780, precatorine, and abrine, would not affect the solvent accessible surface of IDH2 R140Q mutant protein under dynamic conditions. </plain></SENT>
<SENT sid="75" pm="."><plain>The mean square displacement (MSD) for each protein and ligand in IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine over 5000 ps of MD simulation is displayed in Figure 9. </plain></SENT>
<SENT sid="76" pm="."><plain>Root-mean-square fluctuation (RMSF) for each residue over 5000 ps MD simulation is displayed in Figure 10. </plain></SENT>
<SENT sid="77" pm="."><plain>They indicate that IDH2 R140Q mutant protein docking with precatorine and abrine causes similar diffusion constant and flexibility for IDH2 R140Q mutant proteins as AGI-6780. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>After MD simulation, we identify the representative structures of IDH2 R140Q mutant proteins in apo form and in each complex using the RMSD values and graphical depiction of the clusters analysis with a RMSD cutoff of 0.105 nm in Figure 11. </plain></SENT>
<SENT sid="79" pm="."><plain>The docking poses of the representative structures for complexes of IDH2 R140Q mutant proteins with AGI-6780, precatorine, and abrine are illustrated in Figure 12. </plain></SENT>
<SENT sid="80" pm="."><plain>To compare with the result in docking simulation, the IDH2 R140Q mutant protein inhibitor, AGI-6780, has stable hydrogen bonds (H-bonds) with residues Gln316 in both chains of IDH2 R140Q mutant protein and forms a π interaction with residue Val315 in chain B of IDH2 R140Q mutant protein. </plain></SENT>
<SENT sid="81" pm="."><plain>For TCM candidates, they have similar docking poses as docking simulation, which has stable H-bonds with residues Gln316. </plain></SENT>
<SENT sid="82" pm="."><plain>The H-bond occupancy for key residues in complexes of IDH2 R140Q mutant protein with AGI-6780 and top TCM compounds overall 5000 ps of molecular dynamics simulation in Table 1 displayed the stability of H-bonds. </plain></SENT>
<SENT sid="83" pm="."><plain>Analysis of transport pathways for each IDH2 R140Q mutant protein complex illustrated in Figure 13 shows the presumably pathways for small molecule. </plain></SENT>
<SENT sid="84" pm="."><plain>They indicate that IDH2 R140Q mutant protein docking with precatorine and abrine has similar effects of protein conformation as AGI-6780. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="sec4"><title><text><SENT sid="85" pm="."><plain>4. </plain></SENT>
<SENT sid="86" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>This study aims to investigate the potent lead TCM candidates for IDH2 R140Q mutant protein inhibitors against cancers. </plain></SENT>
<SENT sid="88" pm="."><plain>Compared to the IDH2 R140Q mutant protein inhibitor, AGI-6780, the top two TCM compounds, precatorine and abrine, have higher binding affinities with target protein in docking simulation. </plain></SENT>
<SENT sid="89" pm="."><plain>Both of them has H-bonds with residues Gln316 in both chains of IDH2 R140Q mutant protein as AGI-6780. </plain></SENT>
<SENT sid="90" pm="."><plain>After MD simulation, the top two TCM compounds remain as the same docking poses under dynamic conditions. </plain></SENT>
<SENT sid="91" pm="."><plain>In addition, precatorine is extracted from Abrus precatorius L., which has been indicated to have the cytotoxic and proapoptotic effects for breast cancer and several tumor lines. </plain></SENT>
<SENT sid="92" pm="."><plain>Hence, we propose the TCM compounds, precatorine and abrine, as potential candidates as lead compounds for further study in drug development process with the IDH2 R140Q mutant protein against cancer. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="93" pm="."><plain>The research was supported by Grants from the National Science Council of Taiwan (NSC102-2325-B039-001, and NSC102-2221-E-468-027-), Asia University (ASIA100-CMU-2, ASIA101-CMU-2, and 102-ASIA-07), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096). </plain></SENT>
<SENT sid="94" pm="."><plain>This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-03), and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title>Authors' Contribution</title><p>Wen-Yuan Lee, Kuan-Chung Chen, and Hsin-Yi Chen contributed equally to this paper.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="95" pm="."><plain>1ChouI-CLinW-DWangC-HAssociation analysis between Tourette’s syndrome and two dopamine genes (DAT1, DBH) in Taiwanese childrenBioMedicine20133288912-s2.0-84876081328 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="96" pm="."><plain>2YamamotoTHungW-CTakanoTNishiyamaAGenetic nature and virulence of community-associated methicillin-resistant Staphylococcus aureusBioMedicine2013312182-s2.0-84875259470 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="97" pm="."><plain>3JiangYLiXYangWPKM2 regulates chromosome segregation and mitosis progression of tumor cellsMolecular Cell2014531758724316223 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="98" pm="."><plain>4ChangY-MVelmuruganBKKuoW-WInhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cellsBioMedicine2013341481522-s2.0-84878732300 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="99" pm="."><plain>5LeungYMWongKLChenSWDown-regulation of voltage-gated Ca2+ channels in Ca2+ store-depleted rat insulinoma RINm5F cellsBioMedicine2013331301392-s2.0-84881370670 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="100" pm="."><plain>6MahamuniSPKhoseRDMenaaFBadoleSLTherapeutic approaches to drug targets in hyperlipidemiaBioMedicine2012241371462-s2.0-84871609281 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="101" pm="."><plain>7LeissringMAMalitoEHedouinSDesigned inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulinPLoS ONE2010552-s2.0-77956274306e10504 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="102" pm="."><plain>8LinM-CTsaiS-YWangF-YLiuF-HSyuJ-NTangF-YLeptin induces cell invasion and the upregulation of matrilysin in human colon cancer cellsBioMedicine201334174180 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="103" pm="."><plain>9JanssensVGorisJProtein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signallingBiochemical Journal200135334174392-s2.0-003525289411171037 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="104" pm="."><plain>10SuK-PInflammation in psychopathology of depression: clinical, biological, and therapeutic implicationsBioMedicine20122268742-s2.0-84862764317 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="105" pm="."><plain>11JaoC-LHuangS-LHsuK-CAngiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effectsBioMedicine2012241301362-s2.0-84871621268 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="106" pm="."><plain>12LokodyIMetabolism: IDH2 drives cancer in vivoNature Reviews Cancer20131311756757 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="107" pm="."><plain>13DasBRTangriRAhmadFRoyAPatoleKMolecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patientsAsian Pacific Journal of Cancer Prevention201314127261726424460285 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="108" pm="."><plain>14YenKEBittingerMASuSMFantinVRCancer-associated IDH mutations: biomarker and therapeutic opportunitiesOncogene20102949640964172-s2.0-7864999031520972461 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="109" pm="."><plain>15LuCVennetiSAkalinAInduction of sarcomas by mutant IDH2Genes &amp; Development201327181986199824065766 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="110" pm="."><plain>16ChenCLiuYLuCCancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionGenes &amp; Development201327181974198524065765 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="111" pm="."><plain>17GrassianARPagliariniRChiangDYMutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinomaCurrent Opinion in Gastroenterology201430329530224569570 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="112" pm="."><plain>18WangJBDongDFWangMDGaoKIDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivoAsian Pacific Journal of Cancer Prevention201415142743224528069 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="113" pm="."><plain>19WangJBDongDFGaoKWangMDMechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cellsOncology Letters20147365165724520288 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="114" pm="."><plain>20KatsLMReschkeMTaulliRProto-oncogenic role of mutant IDH2 in leukemia initiation and maintenanceCell Stem Cell201414332934124440599 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="115" pm="."><plain>21MylonasEJaninMBawaOIsocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in miceLeukemia2014 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="116" pm="."><plain>22SabitHNakadaMFurutaTCharacterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescenceBrain Tumor Pathology2014 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="117" pm="."><plain>23Bobrovnikova-MarjonEHurovJBTargeting metabolic changes in cancer: novel therapeutic approachesAnnual Review of Medicine201465157170 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="118" pm="."><plain>24ChenCY-CA novel integrated framework and improved methodology of computer-aided drug designCurrent Topics in Medicinal Chemistry20131399659882-s2.0-8487877518723651478 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="119" pm="."><plain>25HuangH-JYuHWChenC-YCurrent developments of computer-aided drug designJournal of the Taiwan Institute of Chemical Engineers20104166236352-s2.0-78649451630 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="120" pm="."><plain>26ChenC-YChenCY-CInsights into designing the dual-targeted HER2/HSP90 inhibitorsJournal of Molecular Graphics and Modelling201029121312-s2.0-7795577255220471294 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="121" pm="."><plain>27YangS-CChangS-SChenH-YChenCY-CIdentification of potent EGFR inhibitors from TCM Database@TaiwanPLoS Computational Biology20117102-s2.0-80055077153e1002189 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="122" pm="."><plain>28TsouY-AChenK-CLinH-CChangS-SChenCY-CUroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics studyPLoS ONE20127112-s2.0-84870550823e50087 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="123" pm="."><plain>29ChenK-CSunM-FYangS-CInvestigation into potent inflammation inhibitors from traditional chinese medicineChemical Biology and Drug Design20117846796882-s2.0-8005261917421801310 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="124" pm="?"><plain>30ChangS-SHuangH-JChenCY-CTwo birds with one stone? </plain></SENT>
<SENT sid="125" pm="."><plain>Possible dual-targeting H1N1 inhibitors from traditional Chinese medicinePLoS Computational Biology20117122-s2.0-84855282742e1002315 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="126" pm="."><plain>31HuangHJJianYRChenCYCTraditional Chinese medicine application in HIV: an in silico studyJournal of Biomolecular Structure &amp; Dynamics201432111223252879 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="127" pm="."><plain>32ChenK-CChangS-SHuangH-JLinT-LWuY-JChenCY-CThree-in-one agonists for PPAR-a, PPAR-γ, and PPAR-d from traditional Chinese medicineJournal of Biomolecular Structure and Dynamics20123066626832-s2.0-8487118181422731403 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="128" pm="."><plain>33ChenKCChangSSTsaiFJChenCYHan ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?Journal of Biomolecular Structure &amp; Dynamics201331111219123523146021 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="129" pm="?"><plain>34ChenK-CYu-Chian ChenCStroke prevention by traditional Chinese medicine? </plain></SENT>
<SENT sid="130" pm="."><plain>A genetic algorithm, support vector machine and molecular dynamics approachSoft Matter201178400140082-s2.0-79953746295 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="131" pm="."><plain>35ChenK-CChangK-WChenH-YChenCY-CTraditional Chinese medicine, a solution for reducing dual stroke risk factors at once?Molecular BioSystems201179271127192-s2.0-8005176068421796302 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="132" pm="."><plain>36ChangT-TChenK-CChangK-WIn silico pharmacology suggests ginger extracts may reduce stroke risksMolecular BioSystems201179270227102-s2.0-8005176719521776525 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="133" pm="."><plain>37TouWIChangS-SLeeC-CChenCY-CDrug design for neuropathic pain regulation from traditional Chinese medicineScientific Reports20133article 8442-s2.0-84880533871 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="134" pm="."><plain>38ChenKCJianYRSunMFChangTTLeeCCChenCYInvestigation of silent information regulator 1 (Sirt1) agonists from traditional Chinese medicineJournal of Biomolecular Structure &amp; Dynamics201331111207121823075283 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="135" pm="."><plain>39TangH-CChenCY-CInvestigation of the novel lead of melanocortin 1 receptor for pigmentary disordersEvidence-Based Complementary and Alternative Medicine2014201413 pages254678 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="136" pm="."><plain>40HuangH-JLeeC-CChenCY-CPharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional chinese medicinEvidence-Based Complementary and Alternative Medicine2014201412 pages830490 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="137" pm="."><plain>41ChenHYChangSSChanYCChenCYDiscovery of novel insomnia leads from screening traditional Chinese medicine databaseJournal of Biomolecular Structure &amp; Dynamics201432577679123730798 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="138" pm="."><plain>42WangFTravinsJDeLaBarreBTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationScience201334061326226262-s2.0-8487762095223558173 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="139" pm="."><plain>43ChenCY-CTCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening In SilicoPLoS ONE2011612-s2.0-79251561193e15939 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="140" pm="."><plain>44TouWIChenCYMay disordered protein cause serious drug side effect?Drug Discovery Today201419436737224184432 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="141" pm="."><plain>45ChenCY-CTouWIHow to design a drug for the disordered proteins?Drug Discovery Today20131819-209109152-s2.0-8487774019123643489 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="142" pm="."><plain>46XueBDunbrackRLWilliamsRWDunkerAKUverskyVNPONDR-FIT: a meta-predictor of intrinsically disordered amino acidsBiochimica et Biophysica Acta: Proteins and Proteomics20101804499610102-s2.0-76849087968 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="143" pm="."><plain>47BrooksBRBruccoleriREOlafsonBDStatesDJSwaminathanSKarplusMCHARMM: a program for macromolecular energy minimization and dynamics calculationsJournal of Computational Chemistry198342187217 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="144" pm="."><plain>48LipinskiCALombardoFDominyBWFeeneyPJExperimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews2001461–33262-s2.0-003528977911259830 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="145" pm="."><plain>49VenkatachalamCMJiangXOldfieldTWaldmanMLigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sitesJournal of Molecular Graphics and Modelling20032142893072-s2.0-003721210212479928 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="146" pm="."><plain>50HessBKutznerCVan Der SpoelDLindahlEGRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulationJournal of Chemical Theory and Computation2008434354472-s2.0-4624909255426620784 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="147" pm="."><plain>51ZoeteVCuendetMAGrosdidierAMichielinOSwissParam: a fast force field generation tool for small organic moleculesJournal of Computational Chemistry20113211235923682-s2.0-7995884170321541964 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="148" pm="."><plain>52FletcherROptimization1969London, UKAcademic Press </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="149" pm="."><plain>53ChovancovaEPavelkaABenesPCAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structuresPLoS Computational Biology20128102-s2.0-84868156224e1002708 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="150" pm="."><plain>54AdelowotanOAibinuIAdenipekunEOdugbemiTThe in-vitro antimicrobial activity of Abrus precatorius (L) fabaceae extract on some clinical pathogensThe Nigerian Postgraduate Medical Journal200815132372-s2.0-4494925015018408781 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="151" pm="."><plain>55ZoreGBAwadVThakreADActivity-directed-fractionation and isolation of four antibacterial compounds from Abrus precatorius L., rootsNatural Product Research20072198388452-s2.0-3574892913317763102 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="152" pm="."><plain>56Shafi SofiMSateeshMKBashirMCytotoxic and pro-apoptotic effects of Abrus precatorius L. on human metastatic breast cancer cell line, MDA-MB-231Cytotechnology20136534074172-s2.0-8487646570423081723 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="153" pm="."><plain>57ReddyVVSirsiMEffect of Abrus precatorius L. on experimental tumorsCancer Research1969297144714512-s2.0-00145444755799161 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="154" pm="."><plain>Disordered disposition predicted by PONDR-Fit. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="155" pm="."><plain>Binding site of IDH2 R140Q mutant protein defined as the volume of AGI-6780 and root-mean-square deviation value between crystallized structure (orange) and docking pose (violet) of AGI-6780. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.002"/></fig></SecTag><SecTag type="FIG"><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="156" pm="."><plain>Chemical scaffold of controls and top two TCM candidates with their scoring function and sources. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.003"/></fig></SecTag><SecTag type="FIG"><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="157" pm="."><plain>Docking pose of IDH2 R140Q mutant protein complexes with (a) AGI-6780, (b) precatorine, and (c) abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.004"/></fig></SecTag><SecTag type="FIG"><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="158" pm="."><plain>Root-mean-square deviations in units of nm for protein and ligand over 5000 ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.005"/></fig></SecTag><SecTag type="FIG"><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p><text><SENT sid="159" pm="."><plain>Radii of gyration for protein over 5000 ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.006"/></fig></SecTag><SecTag type="FIG"><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p><text><SENT sid="160" pm="."><plain>Variation of total energy for complex over 5000 ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.007"/></fig></SecTag><SecTag type="FIG"><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p><text><SENT sid="161" pm="."><plain>Variation of (a) total solvent accessible surface area, (b) hydrophobic surface area, and (c) hydrophilic surface area over 5000 ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.008"/></fig></SecTag><SecTag type="FIG"><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p><text><SENT sid="162" pm="."><plain>Mean square displacement (MSD) for (a) protein and (b) ligand over 5000 ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.009"/></fig></SecTag><SecTag type="FIG"><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p><text><SENT sid="163" pm="."><plain>Root-mean-square fluctuation (RMSF) for residues in (a) chain A and (b) chain B of IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.010"/></fig></SecTag><SecTag type="FIG"><fig id="fig11" orientation="portrait" position="float"><label>Figure 11</label><caption><p><text><SENT sid="164" pm="."><plain>Root-mean-square deviation value (upper left half) and graphical depiction of the clusters with cutoff 0.105 nm (lower right half) for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.011"/></fig></SecTag><SecTag type="FIG"><fig id="fig12" orientation="portrait" position="float"><label>Figure 12</label><caption><p><text><SENT sid="165" pm="."><plain>Docking poses of middle RMSD structure in the major cluster for IDH2 R140Q mutant protein complexes with AGI-6780, precatorine, and abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.012"/></fig></SecTag><SecTag type="FIG"><fig id="fig13" orientation="portrait" position="float"><label>Figure 13</label><caption><p><text><SENT sid="166" pm="."><plain>Analysis of transport pathways for IDH2 R140Q mutant protein complexes with (a) AGI-6780, (b) precatorine, and (c) abrine. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-364625.013"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="167" pm="."><plain>H-bond occupancy for key residues of IDH2 R140Q mutant protein with AGI-6780 and top TCM compounds overall 5000 ps of molecular dynamics simulation. </plain></SENT>
</text></p></caption><table-wrap-foot><fn><p>H-bond occupancy cutoff: 0.3 nm.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
